Skip to main content

Table 4 Change in receptor status by locoregional or distant recurrence

From: Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS)

Receptor

Locoregional recurrence,

number (percentage)

Distant recurrence,

number (percentage)

Estrogen receptor

9/88 (10.2%)

5/49 (10.2%)

Progesterone receptor

22/88 (25.0%)

12/49 (24.5%)

HER2

2/88 (2.3%)

2/49 (4.1%)

  1. HER2, human epidermal growth factor type 2.